Overview
ERC uses a unique patented approach to treat tumours by directly stimulating the patient's immune system. The company's technology employs whole cells and lysates derived from autologous and allogeneic tumor cells as the basis for its immunotherapy treatments.
Something wrong or missing? Send an update. Fixed within 24 hours.